Status:
UNKNOWN
Quantification of Binding and Neutralizing Antibody Levels in COVID-19 Vaccinated Health Care Workers Over 1 Year
Lead Sponsor:
LifeBridge Health
Conditions:
COVID-19 Vaccine
Corona Virus Infection
Eligibility:
All Genders
18+ years
Brief Summary
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic presents a great challenge to global health. The first case was identified in December 2019 in Wuhan, China and since has infe...
Eligibility Criteria
Inclusion
- Adult males or females aged 18 years and older (inclusive) at screening.
- Able and willing (in the investigator's opinion) to comply with all study requirements.
- Willing to discuss their relevant medical history with the study investigators.
- Willing and able to give informed consent prior to study enrollment.
Exclusion
- History of a recent or previous COVID-19 infection per history or as detected by either the PGOLD™COVID-19 IGG/IGM ASSAY or MidaSpot™ COVID-19 Antibody fingerstick test.
Key Trial Info
Start Date :
January 31 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 28 2022
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04910971
Start Date
January 31 2021
End Date
July 28 2022
Last Update
June 2 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sinai Hospital
Baltimore, Maryland, United States, 21215